The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Biora Inc. | COM | 74319F107 | 20,899 | 29,855,847 | SH | SOLE | NA | 29,855,847 | 0 | 0 | |
Biora Inc. | Note 7.250% 12/0 | 74319FAB3 | 65,534 | 103,500,000 | PRN | SOLE | NA | 0 | 0 | 103,500,000 | |
Amryt Pharma PLC | Sponsored ADS | 03217L106 | 61,912 | 8,857,268 | SH | SOLE | NA | 8,857,268 | 0 | 0 | |
Societal CDMO Inc. | Com | 75629F109 | 1,751 | 2,202,420 | SH | SOLE | NA | 2,202,420 | 0 | 0 | |
CAREMAX INC | COM CL A | 14171W103 | 16,289 | 4,487,219 | SH | SOLE | NA | 4,487,219 | 0 | 0 | |
RVL PHARMACEUTICALS PLC | SHS | G6S41R101 | 11,082 | 8,148,832 | SH | SOLE | NA | 8,148,832 | 0 | 0 | |
Omeros Corp | NOTE 6.250%11/1 | 682143AE2 | 18,642 | 21,005,000 | PRN | SOLE | NA | 0 | 0 | 21,005,000 | |
Omeros Corp | NOTE 5.250% 2/1 | 682143AG7 | 20,284 | 35,150,000 | PRN | SOLE | NA | 0 | 0 | 35,150,000 | |
BridgeBio Pharma Inc. | NOTE 2.250% 2/0 | 10806XAD4 | 8,393 | 20,000,000 | PRN | SOLE | NA | 0 | 0 | 20,000,000 | |
PUMA BIOTECHNOLOGY INC | COM | 74587V107 | 5,108 | 1,792,114 | SH | SOLE | NA | 1,792,114 | 0 | 0 | |
Paratek Pharmaceuticals Inc. | NOTE 4.750% 5/0 | 699374AB0 | 7,860 | 9,000,000 | SH | SOLE | NA | 0 | 0 | 9,000,000 |